|
000
| 02808nam 2200481zi 4500 |
|---|
| 001 | 9.911967 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20220916134929 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 220606e202206 onc ob f000 0 eng d |
|---|
| 020 | |a9780660439082 |q(report) |
|---|
| 020 | |a9780660439990 |q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-137/2022E-PDF |
|---|
| 086 | 1 |aHP5-137/1-2022E-PDF |
|---|
| 245 | 00|aNACI rapid response - interim guidance on the use of Imvamune® in the context of monkeypox outbreaks in Canada. |
|---|
| 246 | 17|aInterim guidance on the use of Imvamune® in the context of monkeypox outbreaks in Canada |
|---|
| 246 | 3 |aNational Advisory Committee on Immunization rapid response - interim guidance on the use of Imvamune® in the context of monkeypox outbreaks in Canada |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cJune 2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (25 pages) + |esummary (5 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Réponse rapide du CCNI - orientations provisoires sur l'utilisation d'Imvamuneᴹᴰ dans le contexte des éclosions de variole simienne au Canada. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aAt head of title: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |a"Pub.: 220181." |
|---|
| 500 | |a"Pub.: 220197." |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes bibliographical references (pages 22-25). |
|---|
| 650 | 0|aHuman monkeypox|xVaccination|zCanada. |
|---|
| 650 | 0|aHuman monkeypox|xVaccination|xGovernment policy|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRéponse rapide du CCNI - orientations provisoires sur l'utilisation d'Imvamuneᴹᴰ dans le contexte des éclosions de variole simienne au Canada.|w(CaOODSP)9.911968 |
|---|
| 856 | 40|qPDF|s413 KB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-137-2022-eng.pdf|z(report) |
|---|
| 856 | 40|qPDF|s1.22 MB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-137-1-2022-eng.pdf|z(summary) |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-imvamune-monkeypox.html|z(report) |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-imvamune-monkeypox/summary-june-10-2022.html|z(summary) |
|---|